News for 'ipca-lab'

Indian pharma to get stronger dose of EU mkt access

The European Union's (EU's) offer to slash tariffs on 97.5 per cent of Indian chemical exports to zero is set to give India's pharmaceutical and medical device firms preferential access to the European markets.

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

The tailwind of low price erosion in the US generics market, seen by domestic pharmaceutical companies in calendar year 2023 (CY23), may be reversing slowly, caution analysts. According to the latest data from US-based Centers for Medicare and Medicaid Services (CMMS), price erosion in calendar year 2024 (CY24) on a year-to-date (YTD) basis stood at a high of 15 per cent in the oral solid dosage (OSD) segment compared to a low of 1 per cent in CY23. This erosion, according to a report by Antique Stock Broking, was the highest in the last three years.

Fall 2024 May Not Be A Repeat Of 2018

'We expect the bull-market phase to still persist, but now led by large-caps which offer better valuation and benefit from FII inflows.'
'We expect continued pressure on midcaps, but any sharp correction looks unlikely from here on.'

6 major companies found manufacturing 'substandard' drugs

Alkem Labs was issued drug alerts twice last year -- in June and July -- for its drug Glimekem.

AIDS, TB next big revenue source for pharma majors

24 Indian cos in Forbes Global list

Leading IT companies i-flex Software and Satyam Computers have made their way to Forbes Global's list of 100 'best under a billion' companies in Asia Pacific.

Sensex closes at 12,010, up 37 points

The Sensex closed at 12,009.59 up 37 points. The Nifty gained 7 points to close at 3,479.

Sensex down 25 points at 11,699

The markets opened in green tracking its Asian peers

'Why the fuss over hydroxychloroquine?'

'India is a pharma dada. We can manufacture enough for our people and for the world.'

New drug pricing order challenged in court

The move is expected to delay the introduction of low-priced medicines in the market.

'Is it good to hold stock SIPs for long?'

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

'Bought at 21, now at 49. Hold or sell?'

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Holding too many stocks in your portfolio?

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Sensex ends 184 points higher led by IT; Infosys up 5%

Infosys, TCS, HUL and Reliance Industries were the top gainers of the day.

Sensex in bearish mode; realty, metals shine

The 30-share Sensex dropped 298 points to end at 27,209 and the 50-share Nifty has lost 93 points to end at 8,174.

Pharma in 2014: Deals worth billions and fines worth millions

In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.